Abstract
Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was originally identified as the oncogenic NPM (nucleophosmin)-ALK fusion protein due to a t (2;5) chromosomal translocation in anaplastic large cell lymphomas. Many other chromosomal rearrangements or gene mutations/amplification leading to enhanced ALK activity have subsequently been identified and characterized in a number of human cancer types. The recent reports of EML4 (echinoderm microtubule-associated protein- like 4)-ALK oncogenic proteins in non-small cell lung cancer (NSCLC) and the identification of ALK activating point mutations and gene amplification in neuroblastoma have indicated ALK as a potential major therapeutic target for human cancers. In this review, the role of oncogenic ALK in development of various human cancers is summarized and the efforts and progress of developing small molecule ALK inhibitors as potential cancer therapeutics are updated. Several small molecule ALK inhibitors from distinctive chemical scaffolds in either clinical or preclinical development stage are highlighted and profiled. The challenges and future directions of developing small molecule ALK inhibitors as cancer therapeutics are discussed.
Keywords: Anaplastic lymphoma kinase, chromosomal translocation, anaplastic large-cell lymphoma, inflammatory myofibroblastic tumor, non-small cell lung carcinoma, activating mutation, neuroblastoma, tyrosine kinase inhibitor
Anti-Cancer Agents in Medicinal Chemistry
Title: Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Volume: 10 Issue: 3
Author(s): Mangeng Cheng and Gregory R. Ott
Affiliation:
Keywords: Anaplastic lymphoma kinase, chromosomal translocation, anaplastic large-cell lymphoma, inflammatory myofibroblastic tumor, non-small cell lung carcinoma, activating mutation, neuroblastoma, tyrosine kinase inhibitor
Abstract: Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was originally identified as the oncogenic NPM (nucleophosmin)-ALK fusion protein due to a t (2;5) chromosomal translocation in anaplastic large cell lymphomas. Many other chromosomal rearrangements or gene mutations/amplification leading to enhanced ALK activity have subsequently been identified and characterized in a number of human cancer types. The recent reports of EML4 (echinoderm microtubule-associated protein- like 4)-ALK oncogenic proteins in non-small cell lung cancer (NSCLC) and the identification of ALK activating point mutations and gene amplification in neuroblastoma have indicated ALK as a potential major therapeutic target for human cancers. In this review, the role of oncogenic ALK in development of various human cancers is summarized and the efforts and progress of developing small molecule ALK inhibitors as potential cancer therapeutics are updated. Several small molecule ALK inhibitors from distinctive chemical scaffolds in either clinical or preclinical development stage are highlighted and profiled. The challenges and future directions of developing small molecule ALK inhibitors as cancer therapeutics are discussed.
Export Options
About this article
Cite this article as:
Cheng Mangeng and R. Ott Gregory, Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (3) . https://dx.doi.org/10.2174/1871520611009030236
DOI https://dx.doi.org/10.2174/1871520611009030236 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Calcium Channel Subtypes and Exocytosis in Chromaffin Cells at Early Life
Current Molecular Pharmacology Cellular and Biochemical Actions of Melatonin which Protect Against Free Radicals: Role in Neurodegenerative Disorders
Current Neuropharmacology Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design Nitric Oxide and Dopamine Neurons. Implications for Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents Mitophagy in Neurodegeneration: An Opportunity for Therapy?
Current Drug Targets From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Saponins as Tool for Improved Targeted Tumor Therapies
Current Drug Targets Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Current Alzheimer Research Differential Regulation of Neurotoxin in HIV Clades: Role of Cocaine and Methamphetamine
Current HIV Research Thyroid Hormone Modulation of Immunity: Its Participation in Chronic Stress-Induced Immune Alterations
Current Immunology Reviews (Discontinued) Effect of Withania somnifera Supplementation on Rotenone-Induced Oxidative Damage in Cerebellum and Striatum of the Male Mice Brain
Central Nervous System Agents in Medicinal Chemistry Recognition of Single Stranded and Double Stranded DNA/RNA Sequences in Aqueous Medium by Small Bis-Aromatic Derivatives
Mini-Reviews in Medicinal Chemistry Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry From Rapid to Delayed and Remote Postconditioning: The Evolving Concept of Ischemic Postconditioning in Brain Ischemia
Current Drug Targets Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets